<DOC>
	<DOC>NCT01008007</DOC>
	<brief_summary>The purpose of the study is to assess the safety and effect of Viusid (bags of 4 grams) administration in the treatment of acute fever of viral etiology as diagnosed by clinical, hematologic and serologic parameters. The duration of this open and randomized phase 2 clinical trial will be 6 days. The estimated number of persons with acute fever of viral etiology to be recruited and randomized for the study is 200. The primary outcome measure: platelet, leukocyte and granulocyte count will be assessed at the beginning and the end of the study.</brief_summary>
	<brief_title>Viusid in Adults With Acute Fever of Viral Etiology</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<criteria>Acute fever of viral etiology with less than 72 hours of progression Signed informed consent. Patients under treatment with other antioxidants. Inability to swallow the content of Viusid bags</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Viusid</keyword>
	<keyword>Dietary supplements</keyword>
	<keyword>Acute fever</keyword>
	<keyword>Viral etiology</keyword>
</DOC>